He was Co-Investigator and Medical Director for the UW’s pharmacokinetic study of psilocybin. He is Board Certified in Family Medicine and Addiction Medicine, and holds a PhD in Population Health Sciences. He has worked clinically in the care of patients with substance use disorders in multiple settings including specialist treatment programs, primary care clinics, hospitals, and methadone treatment facilities. He is the Director of the Center for Addictive Disorders at UW Hospital, the Director of UW’s Addiction Medicine Fellowship Program, and a member of the Board of Directors of the American Board of Addiction Medicine. His research interests center on the provision of care to patients with substance use disorders in general medical settings and through innovative systems interventions (such as mobile technology).